[1]
|
S.H. Kennedy and R. Sakina, “Sexual Dysfunction, Depression and the Impact of Antidepressants,” Journal of Clinical Psychopharmacology, Vol. 29, 2009, pp. 157-164. http://dx.doi.org/10.1097/JCP.0b013e31819c76e9
|
[2]
|
R.J. Baldessarini, “Drug Therapy of Depression and Anxiety Disorders. In: L.L. Brunton, J.S. Lazo and K.L. Parker, Ed., Goodman and Gilman’s The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, 2006, pp. 429-459.
|
[3]
|
S. MacDonald, J. Halliday, T. MacEwan, V. Sharkey, S. Farrington, S. Wall and R.G. McCreadie, “Nithsdale Schizophrenia Surveys 24: Sexual Dysfunction. Case-control Study,” British Journal of Psychiatry, Vol. 182, 2003, pp. 50-56. http://dx.doi.org/10.1192/bjp.182.1.50.
|
[4]
|
E.O. Laumann, A. Paik and R.C. Rosen, “Sexual Dysfunction in the United States: Prevalence and Predictors,” Journal of American Medical Association, Vol. 281, 1999, pp. 537-544. Erratum in Journal of American Medical Association, Vol. 281, 1999, p. 1174.
|
[5]
|
A. Ucok, C. Incesu, T. Aker and S. Erkoc, “Sexual Dysfunction in Patients with Schizophrenia on Antipsychotic Medication,” European Psychiatry, Vol. 22, 2007, pp. 328-333. http://dx.doi.org/10.1016/j.eurpsy.2007.01.001.
|
[6]
|
H. Liu-Seifert, B.J. Kinon, C.J. Tennant, J. Sniadecki and J. Volavka, “Sexual Dysfunction in Patients with Schizophrenia Treated with Conventional Antipsychotics or Risperidone,” Journal of Neuropsychiatric Disease and Treatment, Vol. 5, 2009, pp. 47-54. http://dx.doi.org/10.2147/NDT.S4766
|
[7]
|
B.J. Kinon, J.A. Gilmore, H. Liu-Seifert and U.M. Halbreich, “Prevalence of Hyper-prolactinemia in Schizophrenic Patients Treated with Conventional Antipsychotic Medications or Risperidone,” Psychoneuroendocrinology, Vol. 28 (suppl 2), 2003, pp.55-68. http://dx.doi.org/10.1016/S0306-4530(02)00127-0.
|
[8]
|
M. Hummer and J. Hubber, “Hyperprolactinemia and Antipsychotic Therapy in Schizophrenia,” Current Medical Research and Opinion, Vol. 20, 2004, pp. 189-197. http://dx.doi.org/10.1185/030079903125002865
|
[9]
|
M.J. Gitlin, “Psychotropic Medications and their Effects on Sexual Dysfunction: Diagnosis, Biology, and Treatment Approaches,” Journal of Clinical Psychiatry Vol. 55, 1994, pp.406-413.
|
[10]
|
M.H. Pollack, S.Reiter and P. Hammerness, “Genitourinary and Sexual Adverse Effects of Psychotropic Medication,” International Journal of Psychiatry in Medicine, Vol. 22, 1992, pp. 305-327.
|
[11]
|
R.C. Rosen and H. Marin, “Prevalence of Antidepressant-associated Erectile Dysfunction,” Journal of Clinical Psychiatry Vol. 64(Suppl 10), 2003, pp. 5-10. http://dx.doi.org/10.4088/JCP.v64n0301.
|
[12]
|
A.L. Montejo, G. Llorca, J.A. Izquierdo and F. Rico-villademoros, “Incidence of Sexual Dysfunction Associated with Antidepressant Agents: A Prospective Multicentre Study of 1022 Outpatients,” Journal of Clinical Psychiatry, Vol. 62 (suppl 3), 2001, pp. 10-21.
|
[13]
|
A. L. Montejo, S. Majadas, F. Rico-Villademoros, G. Llorca, J. de la Gandara, M. Franco, M. Martin-Carrasco, L. Aquera and N. Prieto; Spanish working Group for the Study of Psychotropic-related Sexual Dysfunction, “Frequency of Sexual Dysfunction in Patients with a Psychotic Disorder Receiving Antipsychotics,” Journal of Sexual Medicine, Vol. 7, 2010, pp. 3404-3413. http://dx.doi.org/10.1111/j.1743-6109.2010.01709.x.
|
[14]
|
J. Buvat, “Hyperprolactinemia and Sexual Function in Men: a Short Review,” International Journal of Impotence Research, Vol. 15, 2003, pp. 373-377. http://dx.doi.org/10.1038/sj.ijir.3901043.
|
[15]
|
M.L. Crismon, T. Argo, and P.F. Buckley, “Schizophrenia”, In: J.T. Dipiro, R.L. Talbert, G.C. Yee, G.R. Matzke, B.G. Wells and L.M. Posey, Ed., Pharmacotherapy: A Pathophysiologic Approach, McGraw-Hill Companies Inc., China, 2008, pp. 1099-1122.
|
[16]
|
R.A. Endow-Eyer, M.M. Mitchell and J.P. Lacro, “Schizophrenia” In: M.A. Koda-Kimble, L.Y. Young, B.K. Aldredge, R.L. Corelli, B.J. Guglielmo, W.A. Kradjan and B.R.Williams Ed., Applied Therapeutics – The Clinical Use of Drugs, Lippincott Williams and Wilkins, Philadelphia, 2009, pp. 78.1-78.34.
|
[17]
|
G.L. Stimmel and M.A. Gutierrez, “Sexual Dysfunction and Psychotropic Medications,” CNS Spectrums, Vol. 11, 2006, pp. 24-30.
|
[18]
|
K.U. Lee, Y.M. Lee, J.M. Nam, H.K. Lee, H.K. Kweon, C.T. Lee and T.Y. Jan, “Antidepressant-induced Sexual Dysfunction among Newer Antidepressants in a Naturalistic Setting,” Psychiatry Investigations, Vol. 7, 2010, pp. 55-59. http://dx.doi.org/10.4306/pi.2010.7.1.55
|
[19]
|
A.J. Gelenberg, C. McGahuey, C. Laukes, G. Okayli, F. Moreno, L. Zentner and P. Delgado, “Mirtazapine Substitution in SSRI-induced Sexual Dysfunction,” Journal of Clinical Psychiatry, Vol. 61, 2000, pp. 356-360. http://dx.doi.org/10.4088/JCP.v61n0506.
|
[20]
|
R.S. Gregorian, K.A. Golden, A. Bahce, C. Goodman, W.J. Kwong and Z.M. Khan, “Antidepressant – induced Sexual Dysfunction,” Annals of Pharmacotherapy, Vol. 36, 2002, pp.1577-1589. http://dx.doi.org/10.1345/aph.1A195.
|
[21]
|
A.H. Clayton and A.L. Montejo, “Major Depressive Disorder, Antidepressants, and Sexual Dysfunction,” Journal of Clinical Psychiatry, Vo. 67 (suppl 60), 2006, pp. 33-37.
|
[22]
|
B.K.Yang and C.F. Donatucci, “Drugs that Effect Male Sexual Dysfunction”, In: J.J. Mulcahy, Ed., Male Sexual Dysfunction: A Guide to Clinical Management. Humana Press Inc., Totowa, New Jersey, 2006, pp. 170.
|
[23]
|
N.K. Ozmenler, T. Karlidere, A. Bozkurt, S. Yetkins, A. Doruk, L. Sutcigil, A. Cansever, O. Uzun, F. Ozgen and A. Ozsahin, “Mirtazapine Augmentation in Depressed Patients with Sexual Dysfunction due to Selective Serotonin Reuptake Inhibitors,” Human Psychopharmacology, Vol. 23, 2008, pp. 321-326. http://dx.doi.org/10.1002/hup.929.
|
[24]
|
S. Kasper and J.P. Olie, “A Meta-analysis of Randomized Controlled Trials of Tianeptine versus SSRI in the Short-term Treatment of Depression,” European Journal of Psychiatry, Vol. 17, 2002, pp.331-340. http://dx.doi.org/10.1016/S0924-9338(02)00651-X.
|
[25]
|
M. Bonierbale, C. Lancon and J. Tignol, “The ELIXIR Study: Evaluation of Sexual Dysfunction in 4557 Depressed Patients in France,” Current Medical Research and Opinion, Vol. 19, 2003, pp. 114-124. http://dx.doi.org/10.1185/0300799039117043.
|
[26]
|
M. Atmaca, M. Kuloglu, E. Tezcan and A. Buyukbayram, “Switching to Tianeptine in Patients with Antidepressant-induced Sexual Dysfunction,”. Human Psychopharmacology, Vol. 18, 2003, pp. 277-280. http://dx.doi.org/10.1002/hup.479.
|
[27]
|
H. El-Shafey, A. Atteya, S. Abuel-Magd, A. Hassanein, A. Fathy and R. Shamloul, Tianeptine can be Effective in Men with Depression and Erectile Dysfunction. Journal of Sexual Medicine, Vol.3, 2006, pp. 910-917. http://dx.doi.org/10.1111/j.1743-6109.2005.00141.x
|
[28]
|
R.S. McIntyre, A. Muller, D.A.Mancini and E.S. Silver, “What to Do if an Initial Antidepressant Fails,” Canadian Family Physician, Vol. 49, 2003, 449-457.
|
[29]
|
I, Schweitzer and V. Tuckwell, “Risk of Adverse Events with the Use of Augmentation Therapy for the Treatment of Resistant Depression,” Drug Safety, Vol.19, 1998, pp.455-464. http://dx.doi.org/10.2165/00002018-199819060-00003.
|
[30]
|
Martindale, The Complete Drug Reference, S.C. Sweetman, Ed., Pharmaceutical Press London 2007, pp. 333-336.
|
[31]
|
D.O. Antonuccio, D. Burns and W.G. Danton, “Antidepressant: A Triumph of Marketing over Science?” Prevention and Treatment, 2002, Available from: http://www. Antidepressantsfacts. com/2002-07-15-Antonuccio-therapy-vs-med.htm/February 2010 (last access on 2011 July 7).
|
[32]
|
L.L. Carpenter, Z. Jocic, J.M. Hall, S.A. Rasmussen and L.H. Price, “Mirtazapine Augmentation in the Treatment of Refractory Depression. Journal of Clinical Psychiatry, Vol. 60, 1999, pp. 45-49. http://dx.doi.org/10.4088/JCP.v60n0110.
|
[33]
|
N.S. Philip, L.L. Carpenter, A.R. Tyrka and L.H. Price, “Augmentation of Antidepressants with Atypical Antipsychotics: A Review of the Current Literature,” Journal of Psychiatric Practice, Vol. 14, 2008, pp. 34-44. http://dx.doi.org/10.1097/01.pra.0000308493.93003.92.
|
[34]
|
S. Smith and A. Gillam, “Sexual Dysfunction – the Forgotten Taboo,” Mental Health Nursing, Vol. 25, 2005, pp. 6-9.
|
[35]
|
R. Gopalakrishnan, K.S. Jacob and A. Kuruvilla, “Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunctions: A Randomized, Double-Blind, Placebo-Controlled, Flexible Dose, Two-Way Crossover Trial. American Journal of Psychiatry, Vol. 163, 2006, pp. 494-499. http://dx.doi.org/10.1176/appi.ajp.163.3.494.
|
[36]
|
J. Volavka, P. Czobor, T.B. Cooper, B. Sheitman, J.P. Lindenmayer, L. Citrome, J.P. McEvoy and J.A. Lieberman, “Prolactin Levels in Schizophrenia and Schizoaffective Disorders Patients Treated with Clozapine, Olanzapine, Risperidone, or Haloperidol,” Journal of Clinical Psychiatry, Vol. 65, 2004, pp. 57-61. http://dx.doi.org/10.4088/JCP.v65n0109
|
[37]
|
D.M. Gardner, R.J. Baldessarini and P. Waraich, “Modern Antipsychotic Drugs: A Critical Overview. Canadian Medical Association Journal, Vol. 172, 2005, pp. 1703-1711. http://dx.doi.org/10.1503/cmaj.1041064.
|
[38]
|
D. Novivk, J.M. Haro, E. Perrin, D. Suarez and J.M. Texeria, “Tolerability of Outpatient Antipsychotic Treatment: 36-month Results from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. European Neuropsychopharmacology, Vol. 19, 2009, pp. 542-550. http://dx.doi.org/10.1016/j.euroneuro.2009.03.003.
|
[39]
|
S. Miyamoto, G.E. Duncan, C.E. Marx and J.A. Lieberman, “Treatment for Schizophrenia: A Critical Review of Pharmacology and Mechanisms of Action of Antipsychotic Drugs,” Molecular Psychiatry Vol. 10, 2005, pp. 79-104. http://dx.doi.org/10.1038/sj.mp.4001556.
|
[40]
|
K. Komossa, C. Rummel-Kluge, H. Hunger, F. Schmid, Schwarz S, Duggan L, W. Kissling and S. Leucht, “Olanzapine versus Other Atypical Antipsychotics for Schizophrenia”, Cochrane Database System Review, 2010 Mar 17; 3:CD006654
|
[41]
|
K. Tani, N. Takei, M. Kawai, K. Suzuki, Y. Sekine, T. Toyoda T, Y. Minabe and N. Mori, “Augmentation of Milnacipran by Risperidone in Treatment for Major Depression,” International Journal of Neuropsychopharmacology, Vol. 7, 2004, pp. 55-58. http://dx.doi.org/10.1017/S146114570300381X.
|
[42]
|
R.A. Mahmoud, G.I. Pandina, I. Turkoz, C. Kosik-Gonzalez, C.M. Canuso, M.J. Kujawa and G.M. Gharabawi-Garibaldi, “Risperidone for Treatment – Refractory Major Depressive Disorder. A Randomized Trial,” Annals of Internal Medicine, Vol. 147, 2007, pp. 593-602.
|
[43]
|
M.M. Berner, M. Hagen, and L. Kriston, “Management of sexual dysfunction due to antipsychotic drug therapy,” Cochrane Databse Systemic Reviews, Vol. 24, 2007, pp. CD003546.
|
[44]
|
L.A. Labbate, “Psychotropics and sexual dysfunction: the evidence and treatments,” Advances in Psychosomatic Medicine, Vol. 29, 2008, pp. 107-130. http://dx.doi.org/10.1159/000126627.
|
[45]
|
A.J. Salerian, W.E. Deibler, B.J. Vittone, S.P. Geyer, L. Drell, N. Mirmirani, J.A. Mirczak, W. Byrd, S.B. Tunick, M. Wax and S. Fleisher, “Sildenafil for psychotropic-induced sexual dysfunction in 31 women and 61 men,” Journal of Sexual and Marital Therapy, Vol. 26, 2000, pp. 133-140. http://dx.doi.org/10.1080/009262300278533.
|
[46]
|
H.G. Nurenberg, P.L. Hensley, A.J. Gelenberg, M. Fava, J. Lauriello and S. Paine, “Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial,” Journal of American Medical Association, Vol. 289, 2003, pp. 56-64. http://dx.doi.org/10.1001/jama.289.1.56.
|
[47]
|
H.G. Nurenberg, P.L. Hensley, J.R. Heiman, H.A. Croft, C. Debattista and S. Paine, “Sildenafil treatment of women with antidepressant-associated controlled trial,” Journal of American Medical Association, Vol. 300, 2008, pp. 395-404. http://dx.doi.org/10.1001/jama.300.4.395.
|
[48]
|
R.N. Marcus, R.D. McQuade and W.H. Carson, D. Hennicken, M. Fava, J.S. Simon, M.H. Trivedi, M.E. Thase and R.M. Berman, “The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second, multicenter, randomized, double-blind placebo – controlled study,” Journal of Clinical Psychopharmacology, Vol. 28, 2008, pp. 156-165. http://dx.doi.org/10.1097/JCP.0b013e31816774f9.
|
[49]
|
D. Baldwin and A. Mayers, “Sexual side-effects of antidepressant and antipsychotic drugs,” Advances in Psychiatric Treatment, Vol. 9, 2003, pp. 202-210. http://dx.doi.org/10.1192/apt.9.3.202.
|